Document Detail

Pregnancy outcome after treatment with the ergot derivative, cabergoline.
MedLine Citation:
PMID:  8829257     Owner:  NLM     Status:  MEDLINE    
The goal of this article is to assess the reproductive safety of cabergoline, a new ergot derivative proposed in hyperprolactinemic disorders. Investigated in different animal species, the drug showed no teratogenic or embryotoxic effects on rabbits. Considering the dose envisaged for humans, large safety margins exist. Our sample consists of 226 pregnancies occuring in 205 women. Follow-up is available for 204. There were 24 miscarriages and three abortions induced because of major malformations (one Down syndrome in a 42-year-old woman, one limb-body wall complex, one hydrocephalus). Two of the 148 single liveborn infants had significant malformations: one megaureter, one scaphocephaly. This series shows no increase in miscarriage rate, a distribution of birthweights and sex ratio within the expected range, and no increased rate of congenital malformations. Follow-up of babies, limited to 107 cases, thus far indicates normal physical and mental development.
E Robert; L Musatti; G Piscitelli; C I Ferrari
Related Documents :
12895457 - Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an elect...
14560067 - Reproductive risk factors related to socioeconomic status in pregnant women in southern...
18818187 - A study of the teratogenic and fetotoxic effects of large doses of barbital, hexobarbit...
9298717 - Asthma in pregnancy.
8469487 - Third-trimester uterine rupture following hysteroscopic uterine perforation.
10796167 - Interventions for preventing or improving the outcome of delivery at or beyond term.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Reproductive toxicology (Elmsford, N.Y.)     Volume:  10     ISSN:  0890-6238     ISO Abbreviation:  Reprod. Toxicol.     Publication Date:    1996 Jul-Aug
Date Detail:
Created Date:  1997-01-09     Completed Date:  1997-01-09     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8803591     Medline TA:  Reprod Toxicol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  333-7     Citation Subset:  IM    
Institut Européen des Génomutations, Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abnormalities, Drug-Induced / etiology*
Birth Weight
Dopamine Agonists / adverse effects*,  therapeutic use
Ergolines / adverse effects*,  therapeutic use
Follow-Up Studies
Hyperprolactinemia / drug therapy
Pregnancy Outcome
Reg. No./Substance:
0/Dopamine Agonists; 0/Ergolines; LL60K9J05T/cabergoline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Teratogenic and lethal effects of long-term hyperthermia and hypothermia in the chick embryo.
Next Document:  Detection of respiratory frequency in the recordings of electrocardiogram, blood pressure or sympath...